Navigation Links
Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
Date:8/5/2008

CAMBRIDGE, Mass., Aug. 5 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced today that Genentech, a collaborator, has moved a modified version of TRX1, MTRX1011A, an anti-CD4 monoclonal antibody, into a phase 1 clinical trial that has begun enrolling patients. The clinical trial is evaluating the safety and tolerability of both single and multiple doses of MTRX1011A. Under the terms of the collaboration agreement between Tolerx and Genentech, Tolerx realized milestones in the first quarter of this year upon selection of the antibody for further development within Genentech's clinical pipeline and upon IND filing. The initiation of the Phase 1 clinical trial resulted in the realization of an additional milestone by Tolerx.

Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx, commented, "We are extremely pleased that our collaboration with Genentech has resulted in the continued advancement of the program, and we look forward to continued progress."

Tolerx and Genentech entered into a collaboration in 2002 to develop and commercialize anti-CD4 monoclonal antibodies. Pursuant to this arrangement, Genentech has the right in all indications to develop, manufacture and commercialize such anti-CD4 monoclonal antibodies. Tolerx will receive additional milestone payments upon further successful development by Genentech of the anti-CD4 monoclonal antibodies in autoimmune or other indications. Tolerx may receive royalties on worldwide net sales of the anti-CD4 monoclonal antibodies that Genentech successfully develops. In lieu of receiving royalties on product sales in the United States, Tolerx has the option to participate in a loss and profit sharing arrangement with Genentech.

About MTRX1011A

MTRX1011A (a modified version of TRX1) is a humanized monoclonal antibody that binds to and down modulates
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
2. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
3. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
4. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
5. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
6. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida
9. Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
10. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
11. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Calif. , July 24, 2014  IRIDEX Corporation ... will release its second quarter 2014 financial results after ... In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, ... the quarter and other business developments. Interested ...
(Date:7/24/2014)... 2014 Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... to discuss the Company,s Second Quarter 2014 financial ... earnings conference call and webcastWhen: , July ... chairman, president and chief executive officer ...
(Date:7/24/2014)... (NYSE MKT: IG), a New Jersey based specialty generic drug ... second quarter ended June 30, 2014. Second Quarter ... in the second quarter of 2014, an increase of 70% ... of $13.3 million for the six months ended June 30, ... 2013 , Total revenues generated from the sale of ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... Control, WASHINGTON, Jan. 10 To help ... risks during times,of health crisis, DuPont (NYSE: ... products, DuPont(TM) Corian(R) solid surface, has been selected,by ... The product,recently was incorporated into a children,s ward ...
... South Korea, Jan. 10 Celltrion, Inc., a ... and CSL Limited, Australia,s leading biopharmaceutical,company, announced today ... supply of CSL 360, an experimental monoclonal antibody ... Phase I clinical trials for CSL,360 are currently ...
Cached Medicine Technology:DuPont Provides Technology for Washington Hospital Center's Emergency Department 2DuPont Provides Technology for Washington Hospital Center's Emergency Department 3DuPont Provides Technology for Washington Hospital Center's Emergency Department 4Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody 2
(Date:7/25/2014)... Gerontological Society of America (GSA) the ... of aging has chosen Heather M. Young, ... Davis, as the 2014 recipient of the Doris ... honor, presented by GSA,s Health Sciences Section, is ... recognition of outstanding and sustained contribution to gerontological ...
(Date:7/25/2014)... As reported by Wood TV 8 in the ... has seen a nearly 500-person increase in heroin related overdose ... 271 between 1999 and 2002, the toll increased to 728 ... other states, drug users in Michigan have turned to heroin ... compared the price of both substances, noting that an 80-milligram ...
(Date:7/25/2014)... As reported by People Magazine in the article Mike ... Sober (7/15), one of the most popular cast stars ... the public about his personal transformation. Now, two years later ... moving on with his life was a challenge. He was ... 2012 and even spent some time in rehab. He took ...
(Date:7/25/2014)... 25, 2014 The Little Gym of ... on Sunday, July 27 at Discovery Green in downtown ... Copperfield, Katy, Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, ... , “We’re thrilled to be attending and performing ... Belcher who owns the Sugarland-Missouri City location. “We believe ...
(Date:7/25/2014)... US (PRWEB) July 25, 2014 ... provider of technology-enabled services for the financial, legal, ... its virtual data room business, Merrill DataSite, has ... Year” presented by GrowthBusiness at the M&A Awards ... recognize the achievements of entrepreneurs, management teams, advisors ...
Breaking Medicine News(10 mins):Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2
... ... Mom’s site, and National Masturbation Month, Good Vibrations ,Celebrates Spring Fever , ... (PRWEB) -- Good Vibrations, the legendary San ... is proud to announce a fun and sexy new resource for moms at goodvibessexymama.com where ...
... ... ability to digitally sign documents online. , ... (PRWEB) May 13, 2010 -- Secured Signing, a web ... sign documents online with trusted, legally binding signatures. Businesses signing documents online reduce costs, ...
... Non surgical procedure restores the ... ... revolutionary hair replication solution recently at their Edina, Mn, office. They utilize a new process ... restores the permanent look of a full head of hair in one day and develops confidence ...
... The joint ... C.V. to provide a consistent supply of logwood extract used in the production of hematoxylin ... smear tests and hematine is used to dye medical sutures. Abbey Color is the world’s ... ...
... ... tumor surgeon, has been named as one of New York,s "Super Doctors" , ... New York, NY (PRWEB) May 12, 2010 For the ... "New York Super Doctor" in a special section of New York Magazine. As one of ...
... ... 12 of their Premier Literacy Suite of software literacy tools. , ... (PRWEB) May 13, 2010 -- Kenneth Grisham, ... innovation to the field of literacy technology. Our reputation is built on creating robust ...
Cached Medicine News:Health News:Three Ways to Put A Spring In Your Step This Month With Good Vibrations 2Health News:Three Ways to Put A Spring In Your Step This Month With Good Vibrations 3Health News:Signing Documents Online, Now Available for Telecom NZ Business Hub Customers 2Health News:Good Look Ink Announces Revolutionary Hair Replication Solution 2Health News:Abbey Color Inc. and Mexicana de Extractos International, S.A. de C.V. Announce Joint Venture Abbymex 2Health News:Abbey Color Inc. and Mexicana de Extractos International, S.A. de C.V. Announce Joint Venture Abbymex 3Health News:Manhattan Orthopaedic Oncologist named as "Super Doctor" for 2010 in the New York Times Magazine 2Health News:Manhattan Orthopaedic Oncologist named as "Super Doctor" for 2010 in the New York Times Magazine 3Health News:Premier Literacy Releases Version 12 of the Most Comprehensive Offering of Literacy Tools Available Today 2Health News:Premier Literacy Releases Version 12 of the Most Comprehensive Offering of Literacy Tools Available Today 3
... In vitro diagnostic reagents for ... (CRP) in human serum as well ... means of particle-enhanced Immunonephelometry using the ... increased levels of a number of ...
Peapod Rongeur, 5.5 length 140 mm....
Suitable for children and adults. New mechanical design of the skull pin holder and the clamp base ensures improved rigid skull fixation....
The Skull Pins are inserted into the receptacles of the Skull Clamp and fixate the head during surgery....
Medicine Products: